Related Experiment Videos
Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates
Insights
Hepatitis B virus vaccine is safe and effective in Chinese neonates. The vaccine elicited a strong antibody response, comparable to older children and superior to adults, establishing crucial immunity.
Area of Science:
- Pediatric immunology
- Vaccinology
- Hepatitis B research
Background:
- Hepatitis B virus (HBV) poses a significant global health risk.
- Neonatal vaccination is critical for preventing vertical transmission and lifelong infection.
- Understanding vaccine immunogenicity in diverse neonatal populations is essential.
Purpose of the Study:
- To evaluate the immunogenicity of a hepatitis B virus vaccine in Chinese neonates.
- To assess the safety and antibody response following a two-dose vaccination schedule.
- To compare the immune response in healthy neonates versus those with passive antibodies.
Main Methods:
- A study involving 38 Chinese neonates (23 healthy, 15 with passive anti-HBs).
- Intramuscular administration of two 20-microgram vaccine doses, one month apart.
- Monitoring of antibody response (anti-HBs) and adverse reactions.
Main Results:
- No adverse reactions were reported in any neonates.
- Susceptible neonates showed a robust antibody response, superior to adults.
- Anti-HBs was detectable in 91% by three months and 96% by six months.
- All neonates achieved detectable anti-HBs after a third dose.
Conclusions:
- The hepatitis B virus vaccine demonstrates excellent safety and immunogenicity in Chinese neonates.
- The vaccine regimen induces a strong and sustained antibody response, crucial for long-term protection.
- Neonatal vaccination is a highly effective strategy for preventing hepatitis B infection.
Abstract:
The immunogenicity of hepatitis B virus vaccine was studied in 38 Chinese neonates, 23 of whom were healthy and susceptible and 15 of whom had passive serum antibody to hepatitis B surface antigen (anti-HBs). Initially, each infant received two 20-micrograms doses of vaccine by the intramuscular route, with a one-month interval between doses. No adverse reactions occurred, and all susceptible neonates had a brisk antibody response that was comparable to that in older infants and children and superior to that in adults. The first dose of vaccine stimulated the production of anti-HBs within one month in 48% of the neonates. Anti-HBs was detectable in the serum of 91% of the vaccinees at the age of three months--that is, two months after the second dose. By the age of six months, 96% of vaccinees had detectable anti-HBs in their serum. All vaccinees developed anti-HBs after a third dose was administered at the age of seven months. High levels of anti-HBs were sustained after vaccination in infants who initially had passive antibodies.